This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.


Defects in the images may include (but are not limited to):


- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

Title: Neoplasm-Specific Polypeptides and Their Uses Applicant(s): Müller-Hermelink et al. Client/Matter No.: 50308/009002 Filing Date: January 26, 2004 Serial No.: Page 1 of 20 Customer No.: 21559






Client/Matter No.: 50308/009002

Filing Date: January 26, 2004 Serial No.: Page 2 of 20 Customer No.: 21559

Fig. 4

Fig. 5



Applicant(s): Müller-Hermelink et al. Client/Matter No.: 50308/009002

Filing Date: January 26, 2004 Serial No.: Page 3 of 20 Customer No.: 21559

Fig. 6





Fig. 7



Client/Matter No.: 50308/009002 Filing Date: January 26, 2004

Serial No.:

Page 4 of 20

tcc Ser 1	tgc Cys	aag Lys	gct Al a	tct Ser 5	ggc Gly	tac Tyr	acc Thr	ttc Phe	act Thr 10	gac Asp	tac Tyr	tat Tyr	ata Ile	aac Asn 15	45
tgg Trp	gtg Val	aag Lys	cag Gln	agg Arg 20	act Thr	gga Gly	cag Gln	G) y ggc	ctt Leu 25	gag Glu	tgg Trp	att	gga Gly	gag Glu 30	90
att Ile	tat Tyr	cct Pro	gga Gly	agt Ser 35	ggt Gly	aat Asn	act Thr	tac Tyr	tac Tyr 40	aat Asn	gag Glu	aag Lys	ttc Phe	aag Lys 45	135
G1y	aag Lys	gcc Ala	aca Thr	ctg Leu 50	act Thr	gca Ala	gac Asp	aaa Lys	tcc Ser 55	tcc Ser	agc Ser	aca Thr	gcc Ala	tac Tyr 60	180
atg Met	cag Gln	ctc Leu	agc Ser	agc Ser 65	ctg Leu	aca Thr	tct Ser	gag Glu	gac Asp 70	tct Ser	gca Ala	gtc Val	tat Tyr	ttc Phe 75	225
tgt Cys	gca Ala	aga Arg	t cg Ser	gga Gly 80	tta Leu	cga Arg	ccc Pro	tat Tyr	gct Ala 85	atg Met	gac Asp	tac Tyr	tgg Trp	ggt Gly 90	270
		acc Thr					٠								

Title: Neoplasm-Specific Polypeptides and Their Uses Applicant(s): Müller-Hermelink et al. Client/Matter No.: 50308/009002 Filing Date: January 26, 2004 Serial No.: Serial No.: Customer No.: 21559

Page 5 of 20

95

58-49/69	•											·
Nucleotide sequence of the variable region of the heavy chain (VH) of antibody NM58-49/69			06		135	180		225		270 ·		<u>د</u> د
f) of		aac Asn 15	gag 9 Glu 30	1	aag 1 Lys 45	tac 1 Tyr 60		ttc 2 Phe 75	1	ggt 2 Gly 90		
 ∑		ata a Ile A	gga g		ttc a Phe I	gcc t Ala 1		tat t Tyr F		tgg g Trp (
chai	CDR1	tat a	att Ile (aag t Lys I	aca g Thr A		gtc t Val		tac t Tyr		
eavy	5	tac t Tyr	tgg a		gag Glu]	agc . Ser '		gca	ane	gac Asp		
the h		gac Asp	gag		aat Asn	tcc Ser	٠,	tct Ser	J-gene	atg Met		
n of		•	ctt Leu 25		tac Tyr 40	tcc Ser 55		gac Asp 70		gct Ala 85		
regio		ttc Phe:	ggc Gly	CDR2	tac Tyr	ааа Lys		gag Glu	3	tat Tyr		
able		acc Thr	cag Gln	U	act Thr	gac Asp		tct Ser	CDR3	CCC		
vari		tac Tyr	gga Gly		aat Asn	gca Ala		aca Thr		cga Arg	•	,
of the		ggc Gly	act Thr		ggt	act Thr		ctg	e	tta Leu		acc Thr
o est		tct Ser 5	agg Arg 20		agt Ser 35	ctg Leu 50		agc Ser 65	D-gene	gga Gly B0		gtc Val
idnei		gct Ala	cag		gga Gly	aca Thr	*	agc Ser	سي	Ser	٠	tca
de se		aag Lys	aag Lys		cct	gcc Ala		ctc Leu		aga Arg		acc Thr
leotik		tgc Cys	gtg Val		tat Tyr	aag Lys		cag Gln		gca Ala		gga Gly
Nuc		tcc Ser	tgg Trp		att Ile	ggc		atg Met		tgt Cys		caa Gln
			Ė									*

Applicant(s): Müller-Hermelink et al. Client/Matter No.: 50308/009002

Serial No.: Filing Date: January 26, 2004

Page 6 of 20

		gtc Val						45
		agc Ser						90
		cag Gln						135
		aac Asn						180
		G] y 999			Leu			225
		ctg Leu			Cys			270
		Phe			Lys		aaa Lys 105	315,

Client/Matter No.: 50308/009002

Serial No.: Filing Date: January 26, 2004

Page 7 of 20

Nucleotide sequence of the variable region of the light chain (VL) of antibody NM58-49/69

4 ت	•	06	135		180		225		270	ر بر	777
tct Ser 15		tat Tyr 30	ctg Leu 45		ttc Phe 60		aga Arg 75	33	tca Ser 90	6	Lys
atc		acc Thr	ctc		agg Arg		agc Ser	CDR3	ggt Gly	ţ	ara Ile
tcc Ser		aac Asn	аад Lyв		gac Asp	•	atc Ile		caa Gln	Ċ	gaa
gcc Ala		gga G1y	cca Pro		CCa		aag Lys		ttt Phe	. (ren
caa Gln		aat Asn	tct Ser		gtc Val		ctc Leu		tgc Cys	i i	аад Lys
gat Asp 10	CDR1	agt Ser 25	cag Gln 40		999 Gly 55		aca Thr 70		tac Tyr 85		acc Thr
gga G1y	Ö	cat His	ggc Gly		tct Ser		ttc Phe		tat Tyr		999 Gly
ctt		gta Val	cca Prọ		ttt Phe		gat Asp		gtt val		999 Gly
agt Ser		att Ile	ааа Lys		cga Arg		aca Thr		gga Gly		gga Gly
gtc Val		agc Ser	cag Gln	CDR2	aac Asn		999 Gly		ctg Leu	:	ttc Phe
cct Pro 5		cag Gln 20	ctg Leu 35	U	tcc Ser 50		tca Ser 65		gat Asp 80		acg Thr
ctg Leu		agt Ser	tac Tyr		gtt Val		gga Gly		gag Glu		tac
tcc Ser		tct Ser	tgg Trp		ааа Lys		agt Ser		gct Ala		ccg Pro
ctc Leu		aga Arg	gaa Glu		tac Tyr		ggc Gly		gag Glu		gtt Val
cca Pro 1		tgc Cys	tta Leu		atc Ile		agt Ser		gtg Val		cat His
									*		

Client/Matter No.: 50308/009002

Filing Date: January 26, 2004 Serial No.:

Page 8 of 20

gat Asp	gtg Val	agg Arg	gag Glu	cct Pro 5	gaa Glu	aat Asn	gaa Glu	att Ile	tct Ser 10	tca Ser	gac Asp	tgc cys	aat Asn	cat His 15		45
ttg Leu	ttg Leu	tgg Trp	aat Asn	tat Tyr 20	aag Lys	ctg Leu	aac Asn	cta Leu	act Thr 25	aca Thr	gat Asp	ccc Pro	aaa Lys	ttt Phe 30		90
gaa Glu	tct Ser	gtg Val	gcc Ala	aga Arg 35	gag Glu	gtt Val	tgc Cys	aaa Lys	tct Ser 40	act Thr	ata Ile	aca Thr	gag Glu	att Ile 45		135
gaa Glu	gaa Glu	tgt Cys	gct Ala	gat Asp 50	gaa Glu	ccg Pro	gtt Val	gga Gly	aaa Lys 55	ggt Gly	tac Tyr	atg Met	gtt Val	tcc Ser 60		180
tgc Cys	ttg Leu	gtg Val	gat Asp	cac His 65	cga Arg	ggc Gly	aac Asn	atc Ile	act Thr 70	gag Glu	tat Tyr	cag Gln	tgt Cys	cac His 75	-	225
cag Gln	tac Tyr	att Ile	acc	aag Lys 80	atg Met	acg Thr	gcc Ala	atc Ile	att Ile 85	ttt Phe	açt Ser	gat Asp	tac Tyr	cgt Arg 90		270
tta Leu	atc Ile	tgt Cys	ggc Gly	ttc Phe 95	atg Met	gat Asp	gac Asp	tgc Cys	aaa Lys 100	aat Asn	gac Asp	atc Ile	aac Asn	att Ile 105	•	315
ctg Leu	aaa Lys	tgt Cys	ggc Gly	agt Ser 110	att Ile	cgg Arg	ctt Leu	gga Gly	gaa Glu 115	aag Lys	gat Asp	gca Ala	cat His	tca Ser 120		360
caa Gln	ggt Gly	gag Glu	gtg Val	gta Val 125	tca Ser	tgc Cys	ttg Leu	gag Glu	aaa Lys 130	ggc Gly	ctg Leu	gtg Val	aaa Lys	gaa Glu 135		405
gca Ala	gaa Glu	gaa Glu	aga Arg	gaa Glu 140	ccc Pro	aag Lys	att Ile	caa Gln	gtt Val 145	tct Ser	gaa Glu	ctc Leu	tgc Cys	aag Lys 150		450
aaa Lys	gcc Ala	att Ile	ctc Leu	cgg Arg 155	gtg Val	gct Ala	gag Glu	ctg Leu	tca Ser 160	tcg Ser	gat Asp	gac Asp	ttt Phe	cac His 165		495
tta Leu	gac Asp	cgg Arg	Cat	tta Leu 170	tat Tyr	ttt Phe	gct Ala	tgc Cys	cga Arg 175	gat. Asp	gat Asp	cgg Arg	gag Glu	.cgt Arg 180		540
ttt Phe	tgt Cys	gaa Glu	aat Asn	aca Thr 185	caa Gln	gct Ala	ggt Gly	gag Glu	ggc Gly 190	aga Arg	gtg Val	tat Tyr	aag Lys	tgc Cys 195		585
ctc Leu	ttt Phe	aac Asn	cat His	aaa Lys 200	ttt Phe	gaa Glu	gaa Glu	tcc Ser	atg Met 205	agt Ser	gaa Glu	aag Lys	tgt Cys	cga Arg 210		630

Applicant(s): Müller-Hermelink et al. Client/Matter No.: 50308/009002

Filing Date: January 26, 2004

Serial No.:

Page 9 of 20

Customer No.: 21559

gaa gca ctt aca acc cgc caa aag ctg att gcc cag gat tat aaa Glu Ala Leu Thr Thr Arg Gln Lys Leu Ile Ala Gln Asp Tyr Lys gtc agt tat tca ttg gcc asa tcc tgt asa agt gac ttg asa sal Val Ser Tyr Ser Leu Ala Lys Ser Cys Lys Ser Asp Leu Lys Lys tac cgg tgc aat gtg gaa aac ctt ccg cga tcg cgt gaa gcc agg Tyr Arg Cys Asn Val Glu Asn Leu Pro Arg Ser Arg Glu Ala Arg ctc tcc tac ttg tta atg tgc ctg gag tca gct gta cac aga ggg Leu Ser Tyr Leu Leu Met Cys Leu Glu Ser Ala Val His Arg Gly cga caa gtc agc agt gag tgc cag ggg gag atg ctg gat tac cga Arg Gln Val Ser Ser Glu Cys Gln Gly Glu Met Leu Asp Tyr Arg 855 ege atg ttg atg gaa gae ttt tet etg age eet gag ate ate eta 900 Arg Met Leu Met Glu Asp Phe Ser Leu Ser Pro Glu Ile Ile Leu age tgt egg ggg gag att gaa cae cat tgt tee gga tta eat ega Ser Cys Arg Gly Glu Ile Glu His His Cys Ser Gly Leu His Arg 945 aaa ggg cgg acc cta cac tgt ctg atg aaa gta gtt cga ggg gag Lys Gly Arg Thr Leu His Cys Leu Met Lys Val Val Arg Gly Glu 990 aag ggg aac ctt gga atg aac tgc cag cag gcg ctt caa aca ctg Lys Gly Asn Leu Gly Met Asn Cys Gln Gln Ala Leu Gln Thr Leu 1035 att cag gag act gac cct ggt gca gat tac cgc att gat cga gct Ile Gln Glu Thr Asp Pro Gly Ala Asp Tyr Arg Ile Asp Arg Ala 350 355 360 1080 ttg aat gaa get tgt gaa tet gta ate eag aca gee tge aaa eat Leu Asn Glu Ala Cys Glu Ser Val Ile Gln Thr Ala Cys Lys His ata aga tot gga gac coa atg ato ttg tog tgc ctg atg gaa cat Ile Arg Ser Gly Asp Pro Met Ile Leu Ser Cys Leu Met Glu His 1170 tta tac aca gag aag atg gta gaa gac tgt gaa cac cgt ctc tta Leu Tyr Thr Glu Lys Met Val Glu Asp Cys Glu His Arg Leu Leu 1215 1260 gag ctg cag tat ttc atc tcc cgg gat tgg aag ctg gac cct gtc Glu Leu Gln Tyr Phe Ile Ser Arg Asp Trp Lys Leu Asp Pro Val 410 ctg tac cgc aag tgc cag gga gac gct tct cgt ctt tgc cac acc Leu Tyr Arg Lys Cys Gln Gly Asp Ala Ser Arg Leu Cys His Thr 425 430 430 1305 cac ggt tgg aat gag acc agc gaa ttt atg cct cag gga gct gtg His Gly Trp Asn Glu Thr Ser Glu Phe Met Pro Gln Gly Ala Val 1350 tto tot tgt tta tac aga cac gcc tac cgc act gag gaa cag gga Phe Ser Cys Leu Tyr Arg His Ala Tyr Arg Thr Glu Glu Gln Gly

Applicant(s): Müller-Hermelink et al. Client/Matter No.: 50308/009002

Filing Date: January 26, 2004 Serial No.:

Page 10 of 20

				gaa Glu 475						1440
				gat Asp 490						1485
				tgc Cys 505						1530
				gac Asp 520						1575
		Asp		aac Asn 535					·	1620
		Ile		ctg Leu 550						1665
		Phe		gtg Val 565						1710
				ata Ile 580						1755
		Lys		gga Gly 595			Phe			1800
		Asp		Ser 610	Tyr					.1845
		Val		tgc Cys 625	Pro			aag Lys 630		1890
		Ile			Thr			gac Asp 645		1935
		Lys			Ser			cgc Arg 660		1980
		Glu			Thr			c cgc Arg 675		2025
		Tyr			Ser			a aac s Asn 690	·	2070
		Gln			Glr			tgt Cys 705		2115
		Lys			Arg			a aaa n Lys 720		2160

Client/Matter No.: 50308/009002

Filing Date: January 26, 2004

Serial No.:

Page 11 of 20

Customer No.: 21559

gta Val	ttt Phe	aag Lys	ctg Leu	cag Gln 725	gag Glu	aca Thr	gag Glu	atg Met	atg Met 730	gac Asp	cca Pro	gag Glu	cta Leu	gac Asp 735	·	2205
									atg Met 745							2250
			Asp						cag Gln 760							2295
									tgc Cys 775							2340
									tac Tyr 790							2385
					Lys				cct Pro 805							2430
atc	ctg Leu	act Thr	aag Lys	gcc Ala 815	Lys	gat Asp	gat Asp	tca Ser	gaa Glu 820	tta Leu	gaa Glu	gga Gly	caa Gln	gtc Val 825		2475
					Leu				gac Asp 835	Gln						2520
					Ile				atc Ile 850	Gln						2565
					Pro				ctg Leu 865	His						2610
					Ala				gca Ala 880	Ala						2655
					Cys					Leu				Lys 900		2700
					Lys					Met				a agc 1 Ser 915		2745
					val					His				gcc s Ala 930		2790
					His					Thi				g Gly 945		2835
														g gtg g Val		2880

agg tta cag ccc gag tgc aaa aag cgc ctc aat gac cgg att gag Arg Leu Gln Pro Glu Cys Lys Lys Arg Leu Asn Asp Arg Ile Glu 965 965 970 970 975

2925

Title: Neoplasm-Specific Polypeptides and Their Uses Applicant(s): Müller-Hermelink et al. Client/Matter No.: 50308/009002

Filing Date: January 26, 2004 Serial No.: Page 12 of 20 Customer No.: 21559

		agt Ser	-	980		~,5	V41.	Ala	985	Ala	Asp	Gly	Phe	Ser 990	2970
gat Asp	ctt Leu	gcc Ala	atg Met	caa Gln 995	gta Val	atg Met	acg Thr	tct Ser	cca Pro	Ser	aag Lys	aac Asn	tac Tyr	att Ile 1005	3015
ctc Leu	Ser	gtg Val	atc Ile	agt Ser 1010	61 y 999	agc Ser	atc Ile	tgt Cys	ata Ile 1015	ьeи	ttc Phe	ctg Leu	att Ile	99c Gly 1020	3060
ctg Leu	atg Met	tgt Cys	gga Gly	cgg Arg 1025	atc Ile	acc Thr	aag Lys	cga Arg	gtg Val 1030	Thr	cga Arg	gag Glu	Leu	aag LysA 1035	3105
gac Asp															

Client/Matter No.: 50308/009002 Filing Date: January 26, 2004 Page 13 of 20 Serial No.: Customer No.: 21559





Fig. 11


Title: Neoplasm-Specific Polypeptides and Their Uses Applicant(s): Müller-Hermelink et al. Client/Matter No.: 50308/009002 Filing Date: January 26, 2004 Serial No.: Page 14 of 20 Customer No.: 21559




Applicant(s): Müller-Hermelink et al Client/Matter No.: 50308/009002

Filing Date: January 26, 2004 Serial No.: Page 15 of 20 Customer No.: 21559






Client/Matter No.: 50308/009002 Filing Date: January 26, 2004 Serial No.: Page 16 of 20 Customer No.: 21559



Title: Neoplasm-Specific Polypeptides and Their Uses Applicant(s): Müller-Hermelink et al. Client/Matter No.: 50308/009002 Filing Date: January 26, 2004 Serial No.: Page 17 of 20 Customer No.: 21559



Title: Neoplasm-Specific Polypeptides and Their Uses Applicant(s): Müller-Hermelink et al. Client/Matter No.: 50308/009002 Filing Date: January 26, 2004 Serial No.: Customer No.: 21559

Page 18 of 20

;	A A	YN YN YN	34. 34.	SY	01 01 01	EA HA		LK LK LK	KI.	YR YR YR	DK DK OF	
1	PFPAGGPP-R PFPAGGPPAR	ADEPVGKGYN ADEPVGKGYM ADEPVGKGYN	CKKAILRVAE CKKAILRVAE CKKAILRVAE	PRSREARLSY PRSREARLSY PRSREARLSY	TDPGADYRID TDPGADYRID TDPGADYRID	AVFSCLYREA AVFSCLYREA AVFSCLYRHA	LLMRACEPII LLMRACEPII LLMRACEPII	EAKEHRVSLK EAKEHRVSLK EAKEHRVSLK	FCPEADSKTM FCPEADSKTN FCPEADSKTM	IIQESALDYR IIQESALDYR IIQESALDYR	SCLMEALEDK SCLMEALEDK SCLMEALEDK	
	QQQQQQQQPQPQP	KSTITEISSC KSTITEIKSC KSTITEIKSC	REPKIQVSEL REPKIQVSEL REPKIQVSEL	KKYRCNVENL KKYRCNVENL KKYRCNVENL	QQALQTLIQE QQALQTLIQE QQALQTLIQE	NETSEFMPQG NETSEFMPQG NETSEFMPQG	LESEDIQIEA LESEDIQIEA LESEDIQIEA	STTVRNDTLQ STTVRNDTLQ STTVRNDTLQ	MRVCKOMIKK FCPEADSKTM MRVCKOMIKR FCPEADSKTM MRVCKOMIKR FCPEADSKTM	SSOCEDQIRI SSOCEDQIRI SSOCEDQIRI	AITPGRGRQM ALTPGRGRQM AITPGRGRQM	
1	0000000070	KFESVAREVC KFESVAREVC KFESVAREVC	EKGLVKEAEE EKGLVKEAEE EKGLVKEAEE	SLAKSCKSDL SLAKSCKSDL SLAKSČKSDL	GEKGNLGMNC GEKGNLGMNC GEKGNLGMNC	ASRLCHTHGW ASALCHTHGW ASRLCHTHGW	CRDIVGNLTE CRDIVGNLTE CRDIVGNLTE	KKKVDVVICL KKKVDVVICL KKKVDVVICL	MMDPELDYTL MRVCKOMIKR MMDPELDYTL MRVCKOMIKR MMDPELDYTL MRVCKOMIKR		САГДІКНИСА САГДІКНИСА САГДІКНИСА	RVTRELKDR* RVTRELKDR*
	QQLPQLPQSS (QQLPQLSS)	NYKLNLTTD? NYKLNLTTD? NYKLNLTTD?	HSOGEVVSCL I	LIAQDYKVSY : LIAQDYKVSY : LIAQDYKVSY :	TLHCLMKVVR (TLHCLMKVVR (TLHCLMKVVR (PVLYRKCQGD ASRLCHTHGW FVLYRKCQGD ASRLCHTHGW PVLYRKCQGD ASRLCHTHGW	QDILIDDLVVE (QDHLDDLVVE (EDVLKICPNI B EDVLKICPNI B EDVLKLCPNI B	QKVFKLQETE NMDPELDYTL QKVFKLQETE NMDPELDYTL QKVFKLQETE NMDPELDYTL	SELEGOVISC LKLRYADORL SELEGOVISC LKLRYADORL SELEGOVISC LKLRYADORL	IFVDPVLHTA CALDIKHHCA AITPGRGROM IFVDPVLHTA CALDIKHHCA ALTPGRGROM IFVDPVLHTA CALDIKHHCA AITPGRGROM	IGLMCGRITK RVTRELKDR*
	GOAGGGGPAG (ISSDCNHLLW PISSDCNHLLW PISSDCNHLLW P	GSIRLGEKDA H GSIRLGEKDA H GSIRLGEKDA H	CREALTTROK I CREALTTROK I CREALTTROK I	CSGLHRKGR 1 HCSGLHRKGR 1 HCSGLHRKGR 1	YEISROWKLD Y YEISROWKLD E	TETCOKLECL C TETCOELECL C ILHORAMDUK C	FSYKEKMACK E FSYKEKMACK E FSYKEKMACK E		DYRLNPMLRK ACKADIPKFC HGLLTKAKDD SELEGQVISC LKLRYADQRL DYRLNPMLRK ACKADIPKFC HGLLTKAKDD SELEGQVISC LKLRYADQRL DYRLNPMLEK ACKADIPKFC HGLLTKAKDD SELEGQVISC LKLEYADQRL		ISGSICILEL 1
	GPGANFVSFV GPGANFVSFV	DVREPENE LODVREPENE LQDVREPENE	CKNDINILKC C		ILSCRGEIEH : ILSCRGEIEH H ILSCRGEIEH H	DCEHRLLELO) DCEHRLLELO) DCEHRLLELO)	IDLGKWCSEK 1 IDLGKWCSEK 1 SRECRAEVQR	FOLVOMKDFR I	NAQIIECLKE NKKOLSTRCH NAQIIECLKE NKKOLSTRCH NAQIIECLKE NKKQLSTRCH	ACKADIPKEC I ACKADIPKEC I ACKADIPKEC I	IKTELCKKEV LNMLKESKAD IKTELCKKEV LNMLKESKAD IKTELCKKEV LNMLKESKAD	SPSKNYILSV
	PARASHSOGO (YRLICGFMDD (YRLICGFMDD (YRLICGFMDD (EGRVYKCLEN HKFEESMSEK EGRVYKCLEN HKFEESMSER EGRVYKCLEN" HKFEESMSEK	MEDESLSPEI I MEDESLSPEI I	EHLYTEKMVE (EHLYTEKMVE (EHLYTEKMVE (LOPALQDKCL 1 LOPALQDKCL 1 TETGGELECL 5	NEKCAIGVTH B NEKCAIGVTH B NEKCAIGVTH B	KNFCSAVOYG P KNFCSAVOYG P KNFCSAVQYG P	DYRLNPMLRK P DYRLNPMLRK P DYRLNPMLRK P	EECLKVNLLK J SECLKVNLLK J SECLKVNLLK J	SSDLAMQVMT S
		DVTRVCPRHT WSNNLAVLEC	TKMTALLESD YRLICGFMDD TKMTALLESD YRLICGFMDD TKMTALLESD YRLICGFMDD	erfcentoag erfcentoag erfcentoag	GENLDYRRML 1 GENLDYRRML 1 GENLDYRRML 1	GDPMILSCLM I GDPMISSCLM I GDPMILSCLM I	ILHQRAMDVK I ILHQRAMDVK I IDLGKWCSEK			ITKROITONT I ITKROITONT I	AAAQEQTGQV B AAAQEQTGQV B	
	FRESALHIL LLFAAGGRNS FRESAALHIL LLFAAGAEKE	AGAGGW KLAEESCRE I AGAGGW KLAEESCRE I	ITEYQCHQYI TKMTAIIESD ITEYQCHQYI TKMTAIIESD ITEYQCHQYI TKWTAIIESD	JOFHLOR HLYFACRODR E JUFHLOR HLYFACROOR E OJEHLUR HLYFACROOR E	KGRQVSSECQ C KGRQVSSECQ C RGRQVSSSCQ C	IQTACKHIRS C IQTACKHIRS C IQTACKHIRS C				ELMDPKCKOM 1 ELMDPKCKOM 1 ELMDPKCKOM 3	DEISSLCAEE A DEISSLCAEE A DEISSLCAEE A	ALNORIEMWS YAAKVAPADG
	MAACGEVERM F	RSGAGACGGW K	VSCLVDHRGN I VSCLVDHRGN I VSCLVDHRGN I	LSSJDFHLÖR H LSSJJFHLÖR H LSSOZEHLÜR H	LLMCLESAVH R LLMCLESAVH R LLMCLESAVH R	NEACE SV NEACE SV NEACE SV	EQGRRI EQGRRI EQGRRI	HDVADN ED-ADN	CRRQLAVSEL E CRRQLRVSEL E CRRQLRVEEL E	LOCLKONKNS E LOCLKONKNS E LOCLKONKNS E	DLOLHCS DLOLHCS DLOLHCS	RVZLQPECKK 3
	HEE	101	201 V 201 V 201 V	301 L 301 L 301 L	101 L 121 L 101 L			701 0	801 C 6	901 901 901 901		1101 איז
	23132 CFR-1 MG160	23132 CFR-1 MG160	23132 CFR-1 RG160	23132 CFR-1 MG160	23132 CFR-1 PG165	23132 CFR-1	23132 CFR-1	23132 CFR-1	23132 CFR-1	23132 CFR-1	23132 CFR-1 MG: 60	23.32

							<u> </u>	leav	y cha	ain s	eque	ence					
												CDR	I				
	TCC Ser																
	CAC His 20													-			
	CI	R II	Ε.														
	TAT Tyr																
	TCC Ser												Met	Asn	Ser 70		
														RII			
	GAG Glu																
				CI	OR II	Ξ											
CTA	TAC	GGT	ATG	GAC	GTT	TGG	GGC	CAA	GGG	AAC	CCT	GTC	ACC	•	312	2	

Human antibody PAM-1 (clone 103/51)

Serial No.:

Customer No.: 21559

Applicant(s): Müller-Hermelink et al. Client/Matter No.: 50308/009002

Filing Date: January 26, 2004

Page 19 of 20

Leu Tyr Gly Met Asp Val Trp Gly Gln Gly Asn Pro Val Thr

Fig. 17

Title: Neoplasm-Specific Polypeptides and Their Uses Applicant(s): Müller-Hermelink et al. Client/Matter No.: 50308/009002

Filing Date: January 26, 2004 Page 20 of 20 Serial No.: Customer No.: 21559

Human antibody PAM-1 (clone 103/51)

Light chain sequence

							Ser		GCC Ala 15	Pro		54
									AGT Ser			108
									(CDR :	ΙΙ	
								_	GAT Asp	_		162
									GGG Gly			216
									TAT Tyr			270
		CD	R II	I								
									AGG Arg 105			324
									GTT Val			378
	AGC Ser 130				399	€						

Fig. 18